GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (HKSE:09688) » Definitions » Earnings per Share (Diluted)

Zai Lab (HKSE:09688) Earnings per Share (Diluted) : HK$-2.74 (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zai Lab Earnings per Share (Diluted)?

Zai Lab's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was HK$-0.39. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-2.74.

Zai Lab's EPS (Basic) for the three months ended in Mar. 2024 was HK$-0.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-2.74.

Zai Lab's EPS without NRI for the three months ended in Mar. 2024 was HK$-0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-2.61.

During the past 3 years, the average EPS without NRIGrowth Rate was 3.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.60% per year.

During the past 9 years, Zai Lab's highest 3-Year average EPS without NRI Growth Rate was 3.00% per year. The lowest was -101.00% per year. And the median was -30.05% per year.


Zai Lab Earnings per Share (Diluted) Historical Data

The historical data trend for Zai Lab's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Earnings per Share (Diluted) Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only -2.37 -2.71 -5.93 -3.58 -2.73

Zai Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -1.02 -0.55 -0.78 -0.39

Competitive Comparison of Zai Lab's Earnings per Share (Diluted)

For the Biotechnology subindustry, Zai Lab's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's PE Ratio distribution charts can be found below:

* The bar in red indicates where Zai Lab's PE Ratio falls into.



Zai Lab Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Zai Lab's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2613.315-0)/966.394
=-2.70

Zai Lab's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-418.304-0)/973.146
=-0.43

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-2.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Zai Lab  (HKSE:09688) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Zai Lab Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Zai Lab's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab (HKSE:09688) Business Description

Industry
Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Wellington Management Group Llp 2102 Investment manager
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Janus Henderson Group Plc 2102 Investment manager
Du Ying 2101 Beneficial owner
Qiming Corporate Gp Iv, Ltd.
Qiming Gp Iv, L.p.
Qiming Venture Partners Iv, L.p.
Qm11 Limited
Fmr Llc 2201 Interest of corporation controlled by you
Invesco Advisers, Inc. 2102 Investment manager
Invesco Developing Markets Fund 2106 Person having a security interest in shares
Baillie Gifford & Co 2102 Investment manager
Citigroup Inc. 2502 Approved lending agent

Zai Lab (HKSE:09688) Headlines

No Headlines